X
[{"orgOrder":0,"company":"Structure Therapeutics","sponsor":"Deep Track Capital","pharmaFlowCategory":"D","amount":"$133.0 million","upfrontCash":"Undisclosed","newsHeadline":"Structure Therapeutics Extends Financing, Advances Diabetes and Obesity Clinical Program and Changes Name from ShouTi","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I"},{"orgOrder":0,"company":"Structure Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$185.3 million","upfrontCash":"Undisclosed","newsHeadline":"Structure Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters\u2122 Option to Purchase Additional American Depositary Shares","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I"},{"orgOrder":0,"company":"Structure Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Structure Therapeutics Initiates Phase 2a Study of Oral GLP-1 agonist GSBR-1290 for the Treatment of Type 2 Diabetes and Obesity","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I"},{"orgOrder":0,"company":"Structure Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","amount":"$300.0 million","upfrontCash":"Undisclosed","newsHeadline":"Structure Therapeutics Announces $300 Million Private Placement Equity Financing","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Structure Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Structure Therapeutics Announces Positive Results from Phase 1b Clinical Study of Oral GLP-1 Receptor Agonist GSBR-1290 and Provides Program Update","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Endocrinology","graph2":"Phase I\/ Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by Structure Therapeutics
Filters
Companies By Therapeutic Area
Details:
The net proceeds will be used to accelerate the development of GSBR-1290, an orally-available small molecule agonist of the GLP-1 receptor, a validated drug target for the treatment of T2DM and obesity.
Lead Product(s):
GSBR-1290
Therapeutic Area: Endocrinology
Product Name: GSBR-1290
Highest Development Status: Phase I/ Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Jefferies
Deal Size: $300.0 million
Upfront Cash: Undisclosed
Deal Type: Private Placement
September 29, 2023
Details:
GSBR-1290 is an orally-available small molecule agonist of the GLP-1 receptor, a validated drug target for the treatment of) T2DM and obesity. The Company is also planning a separate formulation bridging pharmacokinetic study to support the planned transition from capsules to tablets.
Lead Product(s):
GSBR-1290
Therapeutic Area: Endocrinology
Product Name: GSBR-1290
Highest Development Status: Phase I/ Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 29, 2023
Details:
GSBR-1290 is an orally-available small molecule agonist of the GLP-1 receptor, a validated drug target for the treatment of) T2DM and obesity. The Company completed its Phase 1 single ascending dose (SAD) study in September 2022.
Lead Product(s):
GSBR-1290
Therapeutic Area: Endocrinology
Product Name: GSBR-1290
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 25, 2023
Details:
The Company intends to use the net proceeds from the offering primarily for the acceleration of the development of GSBR-1290, and supporting business development activities, and for general corporate purposes.
Lead Product(s):
GSBR-1290
Therapeutic Area: Endocrinology
Product Name: GSBR-1290
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Jefferies
Deal Size: $185.3 million
Upfront Cash: Undisclosed
Deal Type: Public Offering
February 07, 2023
Details:
Proceeds from financing will be used to advance lead programs, including GSBR-1290 in clinical investigation and expand application of its next generation structure-based drug discovery platform to drive innovations in G-protein coupled receptor targeted therapies.
Lead Product(s):
GSBR-1290
Therapeutic Area: Endocrinology
Product Name: GSBR-1290
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Deep Track Capital
Deal Size: $133.0 million
Upfront Cash: Undisclosed
Deal Type: Series B Financing
August 01, 2022